Engineered immune cells target hidden leukemia after transplant
NCT ID NCT07280494
First seen Jan 04, 2026 · Last updated May 23, 2026 · Updated 19 times
Summary
This early-phase study tests whether specially engineered immune cells (CAR-T cells) can safely eliminate small amounts of leftover T-cell leukemia or lymphoma in patients who have already received a stem cell transplant. About 18 participants will receive the treatment and be monitored for side effects and cancer clearance. The goal is to see if this approach can reduce the risk of relapse without causing severe graft-versus-host disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CD7+ T-ALL/LBL are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking University People's Hospital
RECRUITINGBeijing, China, 100044, China
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.